Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Avelumab, Palbociclib and Axitinib in Advanced RCC
NCT05176288 · Bradley A. McGregor, MD · PHASE2 · withdrawn · last registry update 2023-09-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The overall protocol will be changed in a new amendment, which will be resubmitted under the new IND.” | – | Registry record, Bradley A. McGregor, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-30Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Olaparib (NCT02498613)
- 2024-07-16Results posted on the registry: Merck Sharp & Dohme LLC, Lenvatinib + Pembrolizumab (NCT04199104)
- 2024-07-05Results posted on the registry: Dana-Farber Cancer Institute, Avelumab + Talazoparib (NCT02912572)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Durvalumab (NCT04739800)
- 2024-04-12Phase 3 first posted: Hutchmed, Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine + Nab-paclitaxel Plus Gemcitabine (NCT06361888)
- 2024-03-06Phase 3 first posted: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Tocilizumab + Nintedanib (NCT06297096)
- 2024-02-16Phase 3 first posted: Intensity Therapeutics, Inc., INT230-6 + Eribulin (NCT06263231)
- 2024-02-02Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Cediranib (NCT02974621)
- 2024-01-02Results posted on the registry: Deciphera Pharmaceuticals, LLC, Ripretinib + Sunitinib (NCT03673501)
- 2023-10-10Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against FLT1 (NCT06073730)
- 2023-06-18Results posted on the registry: AstraZeneca, Durvalumab + Tremelimumab (Regimen 1) (NCT03298451)
- 2023-06-12Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT05899049)
- 2023-03-28Results posted on the registry: National Cancer Institute (NCI), Cediranib Maleate + Olaparib (NCT02345265)
- 2023-03-07Results posted on the registry: City of Hope Medical Center, axitinib (NCT01385059)
- 2023-01-10Phase 3 first posted: Exelixis, XL092 + Nivolumab (NCT05678673)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision